Page last updated: 2024-12-05

isoeugenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

trans-isoeugenol : The trans-stereoisomer of isoeugenol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1549041
CHEMBL ID445206
CHEBI ID50543
SCHEMBL ID300766
MeSH IDM0111440
PubMed CID853433
CHEMBL ID193598
CHEBI ID50545
SCHEMBL ID57986
MeSH IDM0111440

Synonyms (169)

Synonym
2-methoxy-4-[(z)-prop-1-enyl]phenol
phenol, 2-methoxy-4-propenyl-, (z)-
phenol, 2-methoxy-4-(1-propenyl)-, (z)-
isoeugenol (ii)
cis-4-propenylguaiacol
isoeugenol cis-form
(z)-2-methoxy-4-(prop-1-enyl)phenol
brn 1909603
cis-isoeugenol
(z)-isoeugenol
einecs 227-633-7
cis-2-methoxy-4-propenylphenol
iso-eugenol 1
5912-86-7
2-methoxy-4-[(1z)-prop-1-en-1-yl]phenol
(z)-2-methoxy-4-propenylphenol
CHEBI:50543 ,
CHEMBL445206
2a4kev8dnh ,
unii-2a4kev8dnh
4-06-00-06324 (beilstein handbook reference)
bdbm50410487
SCHEMBL300766
isoeugenol, (z)-
(z)-2-methoxy-4-(1-propenyl)phenol
isoeugenol cis-form [mi]
z-isoeugenol
(z)-4-propenylguaiacol
isoeugenol, z-
isoeugenol, cis-
4-(1-propenyl)-2-methoxyphenol, (z)-
2-methoxy-4-[(1z)-1-propenyl]phenol
(z)-2-methoxy-4-(prop-1-en-1-yl)phenol
DTXSID901025644
BIDD:ER0697
2-methoxy-4-[(e)-prop-1-enyl]phenol
4-hydroxy-3-methoxypropenylbenzene
nsc-6769
1-hydroxy-2-methoxy-4-propenylbenzene
wln: 2u1r dq co1
4-hydroxy-3-methoxy-1-propenylbenzene
phenol, 2-methoxy-4-(1-propenyl)-
2-methoxy-4-propenylphenol
phenol, 2-methoxy-4-propenyl-
4-propenylguaiacol
2-methoxy-4-(1-propenyl)phenol
nsc6769
1-hydroxy-2-methoxy-4-propen-1-ylbenzene
3-methoxy-4-hydroxypropenylbenzene
phenol, 2-methoxy-4-(1-propenyl)-, (e)-
phenol, 2-methoxy-4-propenyl-, (e)-
isoeugenol (i)
einecs 227-678-2
nsc 209522
brn 2046156
(e)-2-methoxy-4-(prop-1-enyl)phenol
isoeugenol trans-form
trans-2-methoxy-4-propenylphenol
nsc-209522
trans-isoeugenol
trans-p-propenylquaiacol
phenol, (e)-
(e)-isoeugenol
5932-68-3
wln: 2u1r dq co1 -e
nsc209522
2-methoxy-4-[(1e)-prop-1-en-1-yl]phenol
NCGC00091470-01
1-(3-methoxy-4-hydroxyphenyl)-1-propane
3-methoxy-4-hydroxy-1-propen-1-ylbenzene
einecs 202-590-7
brn 1909602
nci-c60979
nsc 6769
4-hydroxy-3-methoxy-1-propen-1-ylbenzene
ccris 744
fema no. 2468
ai3-15356
isoeugenol ,
2-methoxy-4-(prop-1-en-1-yl)phenol
97-54-1
NCGC00091470-02
trans-2-methoxy-4-(1-propenyl)phenol
iso-eugenol 2
isoeugenol z
propenylgualacol
trans-4-propenylgualacol
2-methoxy-4-[(1e)-1-propenyl]phenol
CHEBI:50545 ,
isoeugenol e
MLS001065576
smr000112408
CHEMBL193598 ,
BMSE010052
1-(3-methoxy-4-hydroxyphenyl)-1-propene
I0132
AKOS000120575
NCGC00091470-04
NCGC00091470-03
NCGC00254142-01
NCGC00259982-01
tox21_202433
tox21_300303
dtxcid502413
cas-97-54-1
tox21_111138
HMS2268O09
28fsr1nay4 ,
unii-28fsr1nay4
isoeugenol and isomers
3-06-00-04993 (beilstein handbook reference)
unii-5m0mwy797u
hsdb 8044
phenol, 2-methoxy-4-(1-propen-1-yl)-
5m0mwy797u ,
(e)-4-propenylguaiacol
e-isoeugenol
isoeugenol trans-form [mi]
isoeugenol, trans-
isoeugenol, (e)-
isoeugenol, e-
(e)-2-methoxy-4-(1-propenyl)phenol
S5757
STL264281
SCHEMBL57986
NCGC00091470-05
tox21_111138_1
AC-34996
2-methoxy-4-[1-propenyl]phenol
iso-eugenol
3-methoxy-4-hydroxy-1-propenylbenzene
isoeugenol,c&t
isoeugenol,predominantly trans
F1905-7039
DTXSID50872350
mfcd00009285
isoeugenol, cis + trans
isoeugenol, analytical standard
isoeugenol, predominantly trans, analytical standard
(e)-2-methoxy-4-propenyl-phenol
(e)-2-methoxy-4- (1-propenyl)-phenol
2-methoxy-4-propenylphenol (isoeugenol)
2-methoxy-4-(1-propenyl)phenol (acd/name 4.0)
(e)-2-methoxy-4-(1-propenyl)-phenol
2-methoxy-4-(1-propenyl)-phenol
AS-61702
isoeugenol, natural, 99%, fg
(e)-2-methoxy-4-(1-propen-1-yl)phenol
(e)-2-methoxy-4-(prop-1-en-1-yl)phenol
Q27889971
isoeugenol, predominantly trans
phenol, 2-methoxy-4-(1e)-1-propenyl-
HY-N1952
DB14188
EN300-18429
CS-0018270
isoeugenol 2000 microg/ml in acetonitrile
bdbm50548724
iso eugenol
isoeugenol extra nat us
chisoeug
ie trans 92
isougenol
isoeugenol tech
isoeugenol 916
isoeugenol fcc
iso eugenol 88%+
uil135434
Z57953030

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In summary, the maternal toxicity lowest observed adverse effect level (LOAEL) was 250 mg/kg/day based primarily on reduced body weight and gestational weight gain (corrected for gravid uterine weight), and the maternal toxicity no observed adverse effect level (NOAEL) was not determined in this study."( Evaluation of the developmental toxicity of isoeugenol in Sprague-Dawley (CD) rats.
George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ, 2001
)
0.31
" The following subjects are discussed: composition of perfumes, contact with fragrances, diagnosing fragrance allergy, frequency of allergy, clinical picture of allergic contact dermatitis, culprit products, occupational contact dermatitis, and other adverse effects of fragrances."( Fragrances: Contact Allergy and Other Adverse Effects.
de Groot, AC,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Despite the fact that inhibition of UGT by xenobiotics is not usually considered to be a major concern, the involvement of UGT1A1 in BP2 metabolism may have pharmacokinetic and pharmacological consequences, due to the its polymorphisms in humans and its pure estrogenic effect."( Prediction of the metabolic clearance of benzophenone-2, and its interaction with isoeugenol and coumarin using cryopreserved human hepatocytes in primary culture.
de Sousa, G; Pery, A; Rahmani, R; Salle-Siri, R; Teng, S, 2016
)
0.43

Compound-Compound Interactions

The use of multiple freeze (-20 degrees C)-thaw cycles in combination with isoeugenol and polysorbate 80 was investigated as a method for the reduction of numbers of Listeria monocytogenes cells in a bacteriological medium. In this research, assisted by ultrasonic waves, a liquid-liquid microextraction detection method combined with gas chromatography was established for three anaesthetics.

ExcerptReferenceRelevance
"The use of multiple freeze (-20 degrees C)-thaw cycles in combination with isoeugenol and polysorbate 80 was investigated as a method for the reduction of numbers of Listeria monocytogenes cells in a bacteriological medium."( A novel method for the reduction of numbers of Listeria monocytogenes cells by freezing in combination with an essential oil in bacteriological media.
Bremer, PJ; Cressy, HK; Jerrett, AR; Osborne, CM, 2003
)
0.32
" In this research, assisted by ultrasonic waves, a liquid-liquid microextraction detection method combined with gas chromatography was established for three anaesthetics (eugenol, isoeugenol, and methyl isoeugenol) in aquatic food."( Hydrophobic deep eutectic solvent-based ultrasonic-assisted liquid-liquid microextraction combined with GC for eugenol, isoeugenol, and methyl isoeugenol determination in aquatic products.
Feng, M; Guo, M; Ma, S; Yan, J; Zheng, J, 2022
)
0.72
" In this study, the quality and odor characteristics of five groups of nutmeg samples with different degrees of mildew were analyzed by using the responses of an electronic nose combined with chemical profiling."( Detection of Mildewed Nutmeg Internal Quality during Storage Using an Electronic Nose Combined with Chemical Profile Analysis.
Cui, Y; Liang, J; Ouyang, S; Wang, Y; Yan, Y; Yang, R; Yao, Y; Yu, S; Zou, H, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The choice of vehicle for patch test materials is important for the bioavailability and stability of the allergens."( Aspects of pharmaceutical and chemical standardization of patch test materials.
Hansen, J; Kreilgård, B, 1989
)
0.28
"Ethosomes and liposomes are ultra-small vesicles capable of encapsulating drugs and cosmetic ingredients for topical use, thereby potentially increasing bioavailability and clinical efficacy."( Ethosome formulation of contact allergens may enhance patch test reactions in patients.
Andersen, KE; Johansen, JD; Karlberg, AT; Madsen, JT; Simonsson, C; Vogel, S, 2010
)
0.36
" However, it has major drawbacks of very poor bioavailability and solubility."( An appraisal on recent medicinal perspective of curcumin degradant: Dehydrozingerone (DZG).
Hampannavar, GA; Karpoormath, R; Palkar, MB; Shaikh, MS, 2016
)
0.43
" However, the poor stability, solubility, in vivo bioavailability and weak activity of CU greatly limit its clinical application."( Recent advances of analogues of curcumin for treatment of cancer.
Pi, C; Wei, Y; Ye, Y; Zhao, L; Zhao, S, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This estimate is obtained via interpolation of the LLNA dose-response curve and is expressed as the concentration of the chemical required to evince a 3-fold stimulation of proliferation in lymph nodes draining the site of application compared to the vehicle-treated controls (EC3)."( Reproducible prediction of contact allergenic potency using the local lymph node assay.
Basketter, DA; Cadby, P, 2004
)
0.32
" The LCSA provides dose-response information, thereby allowing prediction of the relative ability of a substance to induce sensitization."( A new dendritic cell type suitable as sentinel of contact allergens.
Briechle, D; Peiser, M; Schreiner, M; Stahlmann, R; Wanner, R; Zuberbier, T, 2008
)
0.35
"The aim was to develop an equation that could predict the response to an allergen in a ROAT based on the dose-response curve derived by patch testing."( The dose-response relationship between the patch test and ROAT and the potential use for regulatory purposes.
Andersen, KE; Fischer, LA; Johansen, JD; Menné, T; Voelund, A, 2009
)
0.35
"Results from two human experimental elicitation studies with non-volatile allergens, nickel and the preservative methyldibromo glutaronitrile (MDBGN), were analysed by logistic dose-response statistics."( The dose-response relationship between the patch test and ROAT and the potential use for regulatory purposes.
Andersen, KE; Fischer, LA; Johansen, JD; Menné, T; Voelund, A, 2009
)
0.35
" Dose-response and fabric patch tests were performed, respectively, with filter paper and a cotton sample loaded with fragrance in ethanol-diethylphthalate (DEP) and applied in a Finn Chamber or a Hill Top Chamber."( Fragrance allergy: assessing the safety of washed fabrics.
Baeck, M; Basketter, DA; Bayrou, O; Berthod, D; Germaux, MA; Giordano-Labadie, F; Jacobs, MC; Lainé, G; Laverdet, C; Le Coz, CJ; Martin, L; Marty, JP; Pons-Guiraud, A; Siest, S; Tennstedt, D; van Asten, A; Vigan, M, 2010
)
0.36
"5 mg/kg female that were killed in dosing accidents."( Toxicology and carcinogenesis studies of isoeugenol (CAS No. 97-54-1) in F344/N rats and B6C3F1 mice (gavage studies).
, 2010
)
0.36
" The elicitation doses were calculated, and fitted dose-response curves were drawn."( Can exposure limitations for well-known contact allergens be simplified? An analysis of dose-response patch test data.
Fischer, LA; Johansen, JD; Menné, T; Voelund, A, 2011
)
0.37
" To assess interaction of skin sensitizers in a mixture, a dose-response modeling approach is applied."( A Dose-Response Modeling Approach Shows That Effects From Mixture Exposure to the Skin Sensitizers Isoeugenol and Cinnamal Are in Line With Dose Addition and Not With Synergism.
Ezendam, J; Gremmer, ER; Kienhuis, AS; Slob, W; Vermeulen, JP, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Jason Deodorant Stick Purifying Tea Tree -- 2.5 ozJasonBeauty & Personal Careamyl cinnamal, allantoin, benzyl benzoate, benzyl salicylate, citronellol, behenyl alcohol, ethylhexylglycerin, glyceryl stearate, glycerin, isoeugenol, sodium bicarbonate2024-11-29 10:47:42

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
isoeugenolA phenylpropanoid that is an isomer of eugenol in which the allyl substituent is replaced by a prop-1-enyl group.
isoeugenolA phenylpropanoid that is an isomer of eugenol in which the allyl substituent is replaced by a prop-1-enyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Olfactory Signaling Pathway8028
eugenol and isoeugenol biosynthesis39
volatile cinnamoic ester biosynthesis016
Sensory Perception21568
eugenol and isoeugenol biosynthesis813
volatile cinnamoic ester biosynthesis216

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.01190.100020.879379.4328AID588453
GALC proteinHomo sapiens (human)Potency0.631028.183828.183828.1838AID1159614
GLI family zinc finger 3Homo sapiens (human)Potency27.30600.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency25.21550.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.12150.000657.913322,387.1992AID1259377; AID1259394
hypothetical protein, conservedTrypanosoma bruceiPotency50.11870.223911.245135.4813AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.45630.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency15.08900.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency15.77390.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.17940.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079
GVesicular stomatitis virusPotency2.18760.01238.964839.8107AID1645842
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency68.87400.000723.06741,258.9301AID743085; AID743122
activating transcription factor 6Homo sapiens (human)Potency0.00490.143427.612159.8106AID1159516
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.79400.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Interferon betaHomo sapiens (human)Potency2.18760.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency76.95880.002319.595674.0614AID651631
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)204.17400.00101.979414.1600AID255211
TyrosinaseHomo sapiens (human)IC50 (µMol)33.33000.02304.459310.0000AID1760252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)149.00000.00033.166210.0000AID1682372
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (195)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (56)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (116)

Assay IDTitleYearJournalArticle
AID619934Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 24 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376044Antifungal activity against Epidermophyton floccosum C 114 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID619942Antioxidant activity assessed as ferric to ferrous reduction at 30 ug/ml by FRAP assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376047Antifungal activity against Trichophyton rubrum C 113 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID404687Inhibition of Cochliobolus lunatus CYP53A15 expressed in Escherichia coli2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds.
AID376048Antifungal activity against Epidermophyton floccosum C 114 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID619936Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 36 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376051Antifungal activity against Cryptococcus neoformans ATCC 32264 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID404681Antifungal activity against Cochliobolus lunatus at 5 mM assessed as initial growth inhibition time2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds.
AID1198412Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID619943Antioxidant activity assessed as ferric to ferrous reduction activity at 40 ug/ml by FRAP assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376049Antifungal activity against Candida albicans ATCC 10231 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1198413Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID376055Antifungal activity against Microsporum canis C 112 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376045Antifungal activity against Microsporum gypseum C 115 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID619939Antioxidant activity assessed as superoxide radical scavenging activity after 40 mins by Zhishen's method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID619931Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 6 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376052Antifungal activity against Aspergillus flavus ATCC 9170 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376042Antifungal activity against Trichophyton mentagrophytes ATCC 9972 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID619938Antioxidant activity assessed as residual ABTS+ radical scavenging activity after 30 mins by spectrophotometric analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID1102053Acaricidal activity against Dermatophagoides farinae assessed as mortality at 25.5 ug/cm2 applied as fumes in open container after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID376040Antifungal activity against Microsporum canis C 112 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1198414Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID404682Antifungal activity against Cochliobolus lunatus at 5 mM assessed as radial growth rate2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds.
AID619941Antioxidant activity assessed as ferric to ferrous reduction at 20 ug/ml by FRAP assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID619933Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 18 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID376041Antifungal activity against Microsporum gypseum C 115 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376043Antifungal activity against Trichophyton rubrum C 113 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID337835Antifungal activity against Saccharomyces cerevisiae ATCC 7754 after 2 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID1102051Acaricidal activity against Dermatophagoides pteronyssinus assessed as mortality at 25.5 ug/cm2 applied as fumes in open container after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1102052Acaricidal activity against Dermatophagoides pteronyssinus assessed as mortality at 25.5 ug/cm2 applied as fumes in closed container after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1198411Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1102054Acaricidal activity against Dermatophagoides farinae assessed as mortality at 25.5 ug/cm2 applied as fumes in closed container after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1198409Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID619940Antioxidant activity assessed as ferric to ferrous reduction at 10 ug/ml by FRAP assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID619937Antioxidant activity assessed as residual DPPH radical scavenging activity after 30 mins by spectrophotometric analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID376046Antifungal activity against Trichophyton mentagrophytes ATCC by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1198410Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID376054Antifungal activity against Aspergillus niger ATCC 9029 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID337836Antifungal activity against Candida albicans ATCC 18804 after 2 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID376050Antifungal activity against Saccharomyces cerevisiae ATCC 9763 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376053Antifungal activity against Aspergillus fumigatus ATCC 26934 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID619935Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 30 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID1198415Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID404685Antifungal activity against Cochliobolus lunatus delta bph at 5 mM assessed as radial growth rate2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds.
AID619932Antioxidant activity assessed as inhibition of linoleic acid lipid peroxidation at 100 ug/ml measured after 12 hrs by ferric thiocynate method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Isoeugenol-based novel potent antioxidants: synthesis and reactivity.
AID337837Antifungal activity against Pityrosporum ovale ATCC 14521 after 3 days by broth dilution method1993Journal of natural products, Feb, Volume: 56, Issue:2
Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
AID404680Antifungal activity against Cochliobolus lunatus delta bph at 5 mM assessed as initial growth inhibition time2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
CYP53A15 of Cochliobolus lunatus, a target for natural antifungal compounds.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1511066Antioxidant activity in human HT1080 cells at 100 umol/L by measuring TBARS level by spectrophotometric method relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511062Induction of apoptosis in human U937 cells relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1856375Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as absence of melanin layer at IC50 concentration by transmission electron microscopic analysis
AID1856372Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as decrease in DHN-melanin content by measuring absorption spectra at optical density 275 nm at IC50 concentration incubated for 5 days by UV-vis spectrophotometric analysis
AID1682372Agonist activity at TRPA1 (unknown origin) by calcium imaging assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Discovery of natural TRPA1 activators through pharmacophore-based virtual screening and a biological assay.
AID1856376Induction of cell membrane disruption in Aspergillus fumigatus ATCC 46645 assessed as accumulation of cytoplasmic content at IC50 concentration by transmission electron microscopic analysis
AID1511064Induction of apoptosis in mouse 3LL cells relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1269939Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation at 38 molar ratio after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
An appraisal on recent medicinal perspective of curcumin degradant: Dehydrozingerone (DZG).
AID1494533Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 50 uM after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Benzoxazine derivatives of phytophenols show anti-plasmodial activity via sodium homeostasis disruption.
AID1760252Inhibition of tyrosinase (unknown origin)2020European journal of medicinal chemistry, Sep-01, Volume: 201Kojic acid-natural product conjugates as mushroom tyrosinase inhibitors.
AID1511061Induction of apoptosis in human HepG2 cells relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511068Cell cycle arrest in human A549 cells by propidium iodide staining-based flow cytometric method2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511070Cell cycle arrest in human KB cells by propidium iodide staining-based flow cytometric method2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1682371Agonist activity at TRPA1 (unknown origin) by calcium imaging assay relative to allyl isothiocyanate2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Discovery of natural TRPA1 activators through pharmacophore-based virtual screening and a biological assay.
AID1856367Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as inhibition of conidial and mycelial growth incubated for 5 days by CLSI protocol based microbroth dilution method
AID1856374Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as decrease in number of conidia at IC50 concentration by scanning electron microscopic analysis
AID1511069Cell cycle arrest in human DU145 cells by propidium iodide staining-based flow cytometric method2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511063Induction of apoptosis in human HL60 cells relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511067Cell cycle arrest in human MCF7 cells by propidium iodide staining-based flow cytometric method2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1511065Induction of apoptosis in human SNUC5 cells relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Recent advances of analogues of curcumin for treatment of cancer.
AID1856366Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as inhibition of fungal growth incubated for 5 days by CLSI protocol based microbroth dilution method
AID1856373Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as smooth conidial surface with absence of protrusions at IC50 concentration by scanning electron microscopic analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (245)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (4.90)18.7374
1990's25 (10.20)18.2507
2000's63 (25.71)29.6817
2010's104 (42.45)24.3611
2020's41 (16.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials3 (1.17%)5.53%
Reviews0 (0.00%)6.00%
Reviews12 (4.67%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies3 (1.17%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other239 (93.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]